Intensive blood pressure control (targeting SBP <120 or <130 mmHg) is strongly associated with a reduced risk of cardiovascular events compared to standard control (P<0.001).
Meta-Analysis
Does intensive blood pressure control reduce cardiovascular outcomes in patients with hypertension?
Intensive blood pressure control targeting SBP <120 or <130 mmHg significantly reduces the risk of cardiovascular events in patients with hypertension compared to standard targets.
p-value: p=<0.001
BACKGROUND: This meta-analysis systematically evaluated the impact of intensive (typically targeting systolic BP SBP <120 or <130 mmHg) versus standard (typically targeting SBP <140 mmHg) blood pressure control on cardiovascular outcomes in patients with hypertension. MATERIALS AND METHODS: Relevant randomized controlled trials (RCTs) published up to May 2025 were identified through systematic searches of PubMed, Embase, Web of Science, and the Cochrane Library. A random-effects model was used to calculate pooled relative risks (RRs) with 95% confidence intervals (CIs). RESULTS: < 0.001). Sensitivity analyses confirmed the robustness of these findings. Additionally, the treatment effects varied by sample size, male proportion, smoking prevalence, diabetes status, and follow-up duration. CONCLUSION: Intensive blood pressure control (typically targeting SBP <120 or <130 mmHg) is strongly associated with a reduced risk of cardiovascular events. These findings support adopting lower blood pressure targets in clinical practice while emphasizing the need for individualized patient assessment.
Gao et al. (Tue,) conducted a meta-analysis in Hypertension. Intensive blood pressure control vs. Standard blood pressure control (targeting SBP <140 mmHg) was evaluated on Cardiovascular outcomes (p=<0.001). Intensive blood pressure control (targeting SBP <120 or <130 mmHg) is strongly associated with a reduced risk of cardiovascular events compared to standard control (P<0.001).